319 related articles for article (PubMed ID: 37096236)
1. Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes.
Ma Z; Jin K; Yue M; Chen X; Chen J
J Diabetes Res; 2023; 2023():5891532. PubMed ID: 37096236
[TBL] [Abstract][Full Text] [Related]
2. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
[TBL] [Abstract][Full Text] [Related]
3. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
Nauck MA; D'Alessio DA
Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763
[TBL] [Abstract][Full Text] [Related]
4. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
Frías JP
Expert Rev Endocrinol Metab; 2020 Nov; 15(6):379-394. PubMed ID: 33030356
[TBL] [Abstract][Full Text] [Related]
5. Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes.
Nowak M; Nowak W; Grzeszczak W
Endokrynol Pol; 2022; 73(4):745-755. PubMed ID: 35593668
[TBL] [Abstract][Full Text] [Related]
6. A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health.
Bucheit J; Ayers J; Pamulapati L; Browning A; Sisson E
J Cardiovasc Pharmacol; 2022 Aug; 80(2):171-179. PubMed ID: 35767712
[TBL] [Abstract][Full Text] [Related]
7. Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future.
Caruso I; Giorgino F
Endocrine; 2024 Jun; 84(3):822-835. PubMed ID: 38472620
[TBL] [Abstract][Full Text] [Related]
8. [Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes].
Scheen AJ; Radermecker RP; Paquot N
Rev Med Suisse; 2022 Aug; 18(792):1539-1544. PubMed ID: 36004653
[TBL] [Abstract][Full Text] [Related]
9. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
Urva S; Coskun T; Loghin C; Cui X; Beebe E; O'Farrell L; Briere DA; Benson C; Nauck MA; Haupt A
Diabetes Obes Metab; 2020 Oct; 22(10):1886-1891. PubMed ID: 32519795
[TBL] [Abstract][Full Text] [Related]
10. The new dual gastric inhibitory peptide/glucagon-like peptide 1 agonist tirzepatide in type 2 diabetes: Is the future bright?
Papachristou S; Popovic DS; Papanas N
Diabetes Metab Res Rev; 2021 Nov; 37(8):e3503. PubMed ID: 34626443
[TBL] [Abstract][Full Text] [Related]
11. Beyond glycemia: Comparing tirzepatide to GLP-1 analogues.
Andraos J; Muhar H; Smith SR
Rev Endocr Metab Disord; 2023 Dec; 24(6):1089-1101. PubMed ID: 37526853
[TBL] [Abstract][Full Text] [Related]
12. Tirzepatide: A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus.
Wong E; Cope R; Dima L; Nguyen T
Am J Ther; 2023 Jan-Feb 01; 30(1):e26-e35. PubMed ID: 36516422
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.
Nauck MA; Mirna AEA; Quast DR
Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380
[TBL] [Abstract][Full Text] [Related]
14. Perspectives on weight control in diabetes - Tirzepatide.
Várkonyi TT; Pósa A; Pávó N; Pavo I
Diabetes Res Clin Pract; 2023 Aug; 202():110770. PubMed ID: 37279858
[TBL] [Abstract][Full Text] [Related]
15. Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
Bradley CL; McMillin SM; Hwang AY; Sherrill CH
Ann Pharmacother; 2023 Jul; 57(7):822-836. PubMed ID: 36367094
[TBL] [Abstract][Full Text] [Related]
16. Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes.
Kaneko S
touchREV Endocrinol; 2022 Jun; 18(1):10-19. PubMed ID: 35949358
[TBL] [Abstract][Full Text] [Related]
17. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
Willard FS; Douros JD; Gabe MB; Showalter AD; Wainscott DB; Suter TM; Capozzi ME; van der Velden WJ; Stutsman C; Cardona GR; Urva S; Emmerson PJ; Holst JJ; D'Alessio DA; Coghlan MP; Rosenkilde MM; Campbell JE; Sloop KW
JCI Insight; 2020 Sep; 5(17):. PubMed ID: 32730231
[TBL] [Abstract][Full Text] [Related]
18. Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist.
Tall Bull S; Nuffer W; Trujillo JM
J Diabetes Complications; 2022 Dec; 36(12):108332. PubMed ID: 36375235
[TBL] [Abstract][Full Text] [Related]
19. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.
Thomas MK; Nikooienejad A; Bray R; Cui X; Wilson J; Duffin K; Milicevic Z; Haupt A; Robins DA
J Clin Endocrinol Metab; 2021 Jan; 106(2):388-396. PubMed ID: 33236115
[TBL] [Abstract][Full Text] [Related]
20. Tirzepatide: Clinical review of the "twincretin" injectable.
Krauss Z; Hintz A; Fisk R
Am J Health Syst Pharm; 2023 Jul; 80(14):879-888. PubMed ID: 37070418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
